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Immune-specific genes as well as genes responsible for the formation and integrity of the epidermal 
barrier have been implicated in the pathogeneses of allergic sensitization. This study sought to 
determine whether an epistatic effect (gene-gene interaction) between genetic variants within 
interleukin 4 receptor (IL4R) and filaggrin (FLG) genes predispose to the development of allergic 
sensitization. Data from two birth cohort studies were analyzed, namely the Isle of Wight (IOW; 
n = 1,456) and the Manchester Asthma and Allergy Study (MAAS; n = 1,058). In the IOW study, one 
interaction term (IL4R rs3024676 × FLG variants) showed statistical significance (interaction term: 
P = 0.003). To illustrate the observed epistasis, stratified analyses were performed, which showed that 
FLG variants were associated with allergic sensitization only among IL4R rs3024676 homozygotes (OR, 
1.97; 95% CI, 1.27–3.05; P = 0.003). In contrast, FLG variants effect was masked among IL4R rs3024676 
heterozygotes (OR, 0.53; 95% CI, 0.22–1.32; P = 0.175). Similar results were demonstrated in the MAAS 
study. Epistasis between immune (IL4R) and skin (FLG) regulatory genes exist in the pathogenesis of 
allergic sensitization. Hence, genetic susceptibility towards defective epidermal barrier and deviated 
immune responses could work together in the development of allergic sensitization.
Allergic sensitization, defined as the propensity to produce immunoglobulin E (IgE) antibodies in response to 
environmental and food antigens, affects up to 50% of the general population and is a common thread linking and 
predisposing to different manifestations of allergic diseases, including asthma, eczema, and rhinitis1,2. Hence, in 
order to understand the immunologic dysregulation that characterizes allergic diseases, it is crucial to study the 
etiology of allergic sensitization. Genetic susceptibility, in addition to environmental and immunologic factors, 
has been implicated in the pathogenesis of allergic sensitization.
Genome-wide association studies (GWAS) and candidate-gene studies have identified genetic variants across 
different genes that relate to the development of allergic sensitization3–7. Genetic variants that regulate immune 
responses such as interleukin 4 receptor (IL4R), through which IL-4 and IL-13 cytokines exert their biological 
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regulation of IgE production, have been investigated in relation to allergic sensitization due to their relevant 
function in allergic inflammatory process8. It has also been suggested that loss-of-function variants within the 
filaggrin gene (FLG), leading to impaired skin barrier that is characterized by enhanced allergen penetration, 
increase the risk of allergic sensitization9,10. Hence, immune specific genes as well as genes responsible for the 
formation of functional skin barrier may both be involved in the pathogenesis of allergic sensitization. Taking a 
hypothesis-driven candidate-gene approach, we aimed to determine whether genetic variants within IL4R and 
FLG genes have an epistatic effect (interact) on allergic sensitization.
Thus far, genetic variants identified in GWAS have yielded modest effect sizes (i.e., risk/odds ratios of 1.1 to 
1.5) that explain small proportions of the observed phenotypic variations of complex diseases11. One explanation 
is that the GWAS considers the effect of single nucleotide polymorphisms (SNPs) in isolation, while genes may 
require interaction with other genes in causal pathway for clinical manifestation. Thus, gene-gene interactions 
(epistasis), a setting in which the effect of one genetic variant on a phenotype depends on the genotype of another 
variant elsewhere in the genome, have contributed to improve results of genetic association studies12,13. Epistasis 
between immune related genes has been investigated previously in relation to the development of allergic sensiti-
zation8,14–16; however, epistasis between immune regulatory genes (e.g., IL4R) and genes that regulate the forma-
tion and function of the skin barrier (e.g., FLG) has not been previously reported.
We hypothesized that genetic predisposition towards defective epidermal barrier (i.e., FLG loss-of-function 
variants) in combination with genetic susceptibility for immune dysregulation (i.e., IL4R variants) is associated 
with increased risk of developing allergic sensitization. The rationale is that exposing immune-related cells resid-
ing in the epidermis to allergenic substances that easily penetrate the defective epidermal barrier may increase 
the risk of allergic sensitization in genetically susceptible individuals. Therefore, exploring the epistatic effect 
between two functionally different genes that possibly work in concert can provide new insights into the etiology 
of allergic sensitization. To this end, we analyzed data from two population-based birth cohort studies, namely 
the Isle of Wight birth cohort (IOW; discovery study) and the Manchester Asthma and Allergy Study (MAAS; 
replication study).
Methods
Isle of Wight birth cohort study – Discovery population. Study population. An unselected popula-
tion-based birth cohort was recruited from all births (n = 1,536) occurring between January 1989 and February 
1990 on the Isle of Wight, UK, to prospectively study the natural history and etiology of allergic conditions. 
After exclusion of adoptions, perinatal deaths, and refusal for follow-up, written informed consent was obtained 
from parents to enroll 1,456 (95%) newborns, with follow-up assessments conducted at 1, 2, 4, 10, and 18 years 
of age. Ethics approvals were obtained from the Isle of Wight Local Research Ethics Committee (now named the 
National Research Ethics Service, NRES Committee South Central – Southampton B) at recruitment and for the 
subsequent follow-ups (06/Q1701/34). The study was conducted in accordance with principles and guidelines of 
the Declaration of Helsinki for medical research involving human subjects.
Skin prick test. Skin prick tests (SPTs) were performed on most children attending the research center at ages 4 
(n = 982), 10 (n = 1,036), and 18 (n = 853) years to determine their allergic sensitization status. A standard bat-
tery of common allergens (ALK-Albello, Horsholm, Denmark) was tested. Inhalant allergens tested were house 
dust mite, cat, dog, Alternaria alternata, Cladosporium herbarium, grass pollen mix, and tree pollen mix. Food 
allergens tested were cows’ milk, soya, hens’ egg, peanut and cod. Positive and negative controls were included. 
Allergic sensitization was defined by having a positive SPT to at least one allergen test with mean wheal diameter 
of 3 mm greater than the negative control.
Genotyping. Genomic DNA was extracted from blood or saliva samples of study participants (n = 1,211). 
FLG variants R501X, 2282del4, and S3247X were genotyped using GoldenGate Genotyping Assays on the 
BeadXpressVeracode platform (Illumina, Inc, SanDiego, CA, USA) per Illumina’s protocol. Individuals carry-
ing the minor allele for at least one of the FLG variants R501X, 2282del4, or S3247X were classified as having 
filaggrin haploinsufficiency. Detailed information on FLG genotyping is provided by Ziyab et al.17. Single nucleo-
tide polymorphisms (SNPs; n = 13; rs8832, rs1110470, rs1805011, rs1805012, rs2057768, rs3024604, rs3024622, 
rs3024676, rs3024685, rs4787423, rs6498012, rs12102586, and rs16976728) spanning the genomic region of IL4R 
gene were selected for genotyping based on a tagging scheme aiming to capture common/functional genetic vari-
ants that are related to allergic conditions across the IL4R gene18 (see Supplementary Methods online for detailed 
information on genotyping).
Manchester Asthma and Allergy study – Replication population. Study population. MAAS is a 
population-based birth cohort study described in detail elsewhere (registration: ICRCTN72673620)19. Subjects 
were recruited prenatally from 1995 to 1997, and a total of 1,184 participants were born into the study, of whom 
1,058 Caucasians were included in this analysis. Subjects were followed prospectively and attended follow-up 
clinics with a clinical assessment including sample collection, questionnaire data collection, and lung function 
assessment. The study was approved by the North West – Greater Manchester East Research Ethics Committee; 
parents gave written informed consent, and children gave assent if appropriate. The study was conducted in 
accordance with principles and guidelines of the Declaration of Helsinki for medical research involving human 
subjects.
Skin prick test. We ascertained sensitization to allergens by skin prick testing at ages 5 years (n = 827), 8 years 
(n = 818), and 11 years (n = 728) to a panel of allergens (house dust mite [Dermatophagoides pteronyssinus], 
cat, dog, mixed grasses, mixed trees, mixed molds, peanut, milk, and egg [Bayer, Elkahrt, IN, USA]). Allergic 
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sensitization was defined as having a positive SPT to at least one allergen with mean wheal diameter of 3 mm 
greater than the negative control.
Genotyping. FLG genotyping was performed with probes and primers as previously described20. Genotyping for 
R501X and S3247X loss-of-function mutations was performed with a TaqMan-based allelic discrimination assay 
(Applied Biosystems, Cheshire, UK). Mutation 2282del4 was genotyped by sizing of a fluorescently labelled PCR 
fragment on a 3100 DNA Sequencer (ABI). Data were analyzed as combined carriage of a FLG null allele; that 
is, if a child carried 1 or more of the 3 genetic variations, he or she was considered filaggrin haploinsufficiency. 
Genotyping for IL4R SNP rs3024676 was also carried out using standard TaqMan assay conditions (assay ID: 
C__22272514_10).
Statistical analysis. In the IOW study, deviation from Hardy-Weinberg Equilibrium (HWE) was tested for 
each of the 13 genotyped IL4R SNPs using goodness-of-fit χ2 tests (see Supplementary Table S1 online) and esti-
mates of linkage disequilibrium (LD) between SNPs were calculated using Dʹ and r2 measures (see Supplementary 
Fig. S1). SNPs that deviated from HWE (P < 0.05) were excluded from this analysis (1 SNP; rs3024622). Since 
allergic sensitization (the outcome variable) was repeatedly measured at ages 4, 10, and 18 years, generalized 
linear statistical models were applied with parameters estimated via generalized estimating equations (GEE) to 
account for the correlated observations and the within-child effect21. For each IL4R SNP, the best fitting genetic 
model (additive, dominant, recessive, or heterosis; see Supplementary Methods online) was determined based on 
the quasi-likelihood under the independence model criterion (QIC), which is used to assess the goodness-of-fit 
in GEEs22. In this selection step, GEE models included the main effect of the respective IL4R SNP (under the 
respective genetic model) as the independent variable (age and sex were included as potential confounders) and 
the repeated measures of allergic sensitization were considered as the outcome variable; for each IL4R SNP, the 
genetic model with the lowest QIC value was selected as the best fitting model. Using the best fitting genetic 
model for each of IL4R SNPs, the statistical significance of interaction terms between IL4R SNPs and FLG variants 
were tested in logistic regression models (total of 12 tests). To adjust for multiple testing, we controlled the false 
discovery rate (FDR) to obtain multiple-testing corrected p-values associated with the interaction terms23. In the 
replication population (MAAS cohort), we only tested statistical interactions between IL4R SNPs with FLG var-
iants that demonstrated statistical significance (FDR P < 0.05) in the discovery study. Age and sex were included 
in all generalized linear equations as potential confounders. The procedure GENMOD in SAS 9.4 (SAS, Gary, 
NC, USA) was applied. Odds ratios (ORs) and their associated 95% confidence intervals (CIs) were estimated.
Data availability. The datasets analyzed during the current study are available from the corresponding 
author on reasonable request.
Results
Description of study populations. In both studies allergic sensitization increased in prevalence with age. 
For example, among the IOW study participants, SPT positivity was observed in 19.7% at 4 years, 26.9% at 10 
years, and 41.4% at 18 years of age (Table 1). In the MAAS cohort, the proportion of positive SPTs increased from 
29.0% to 35.2% between ages 5 and 11 years. The combined proportion of carrying the minor allele(s) of FLG 
variants R501X, 2282del4, and S3247X was 10.3% in the IOW cohort and 9.9% in the MAAS cohort (Table 1).
Selecting best-fitting genetic model and screening for epistasis. In the IOW cohort study (dis-
covery study), the best-fitting genetic model (additive, dominant, recessive, or heterosis) was selected for each of 
the twelve IL4R SNPs based on the smallest QIC value calculated for generalized linear models fitted using GEE 
(see Supplementary Table S2); these models tested the association between IL4R SNPs under the different genetic 
models with the repeated measurements of allergic sensitization. Subsequently, twelve interaction terms (IL4R 
SNP × FLG variants) were evaluated using logistic regression equations (Table 2). After correcting for multiple 
testing, one interaction term (IL4R rs3024676 × FLG variants) demonstrated statistical significance (interaction 
term: P = 0.003, FDR corrected P = 0.036, Table 2).
Illustrating the epistatic effect between FLG and IL4R – IOW cohort study. First, we assessed the 
association of FLG variants and IL4R rs3024676 with allergic sensitization to determine their independent effects. 
FLG variants showed positive association with allergic sensitization based on results of repeated measurements 
analysis that covered the period from 4 to 18 years of age (OR, 1.47; 95% CI, 1.01–2.14; P = 0.046; Table 3). 
In contrast, the association between IL4R rs3024676 (heterosis genetic model: AA/CC vs. AC) and repeated 
measurements of allergic sensitization did not demonstrate statistical significance (OR, 1.25; 95% CI, 0.97–1.62; 
P = 0.085; Table 3). However, IL4R rs3024676 was associated with increased risk of allergic sensitization at age 10 
years (OR, 1.56; 95% CI, 1.12–2.16; P = 0.008).
Next, to illustrate the possible epistasis (IL4R rs3024676 × FLG variants), the association between FLG variants 
with allergic sensitization was stratified by IL4R rs3024676 genotypes. The stratified analysis showed that FLG 
variants statistically significantly associated with increased risk of allergic sensitization among IL4R rs3024676 
homozygotes (repeated measurements analysis: OR, 1.97; 95% CI, 1.27–3.05; P = 0.003; Table 4). In contrast, FLG 
variants did not pose any increased risk for allergic sensitization among IL4R rs3024676 heterozygotes (repeated 
measurements analysis: OR, 0.53; 95% CI, 0.22–1.32; P = 0.175; Table 4). Hence, indicating that IL4R rs3024676 
is a possible effect modifier of the association between FLG variants with allergic sensitization.
Replicating the epistasis between FLG and IL4R – MAAS cohort. In the MAAS cohort (replication 
study), FLG variants demonstrated a statistically significant association with the repeated measurements of aller-
gic sensitization status (OR, 1.73; 95% CI, 1.1.3–2.63; P = 0.011; Table 5). Similar to findings from the IOW cohort 
www.nature.com/scientificreports/
4SCIENTIFIC REPoRTS |  (2018) 8:3221  | DOI:10.1038/s41598-018-21459-x
study, there was no association between IL4R rs3024676 and allergic sensitization (repeated measurements anal-
ysis: OR, 0.87; 95% CI, 0.65–1.15; P = 0.328; Table 5). When testing for statistical interaction on a multiplicative 
scale, the interaction term (IL4R rs3024676 × FLG variants) did not demonstrate statistical significance (inter-
action term: P = 0.536) in the MAAS cohort. However, similar to findings from the IOW study, in the analysis 
stratified by IL4R rs3024676 genotype, FLG variants were associated with increased risk of allergic sensitization 
among IL4R rs3024676 homozygotes (repeated measurements analysis: OR, 1.93; 95% CI, 1.12–3.31; P = 0.017; 
Table 6). And there was no association between FLG variants and allergic sensitization among IL4R rs3024676 
heterozygotes (repeated measurements analysis: OR, 1.44; 95% CI, 0.66–3.12; P = 0.360; Table 6).
Discussion
The current study demonstrates an epistatic (gene-gene interaction) effect between genetic variants in the FLG 
and IL4R genes on the development of allergic sensitization in two independent population-based birth cohort 
studies. In the IOW and MAAS study cohorts, FLG variants increased the risk of allergic sensitization in the total 
study samples; however, in the analysis stratified by IL4R rs3024676 SNP genotypes, FLG variants only increased 
the risk of allergic sensitization among participants who carry the homozygous genotypes (i.e., AA or CC) of IL4R 
rs3024676 SNP. Subsequently, the effect of FLG variants on the risk of allergic sensitization was masked among 
those with the heterozygous genotype (i.e., AC) of IL4R rs3024676 SNP. Hence, results of this report indicate that 
IL4R rs3024676 SNP is a possible effect modifier of the association between FLG variants and allergic sensitiza-
tion; suggesting an interplay between immune-specific (IL4R) and skin-specific (FLG) genes in the pathogenesis 
of allergic sensitization.
The role of IL4R genetic variants in the development of allergic disorders and sensitization is well documented 
in the scientific literature8,24,25. Briefly, both IL-4 and IL-13 cytokines can activate IL4R, which subsequently acti-
vates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways leading to 
the synthesis of IgE26. Hence, IL4R plays a central as well as a critical role in the regulation of IgE-mediated aller-
gic inflammation. On the other hand, the role of epidermal barrier defects in the development of allergic man-
ifestation has been further highlighted after the discovery of FLG loss-of-function variants20. The mechanically 
impaired epidermal barrier allows allergen penetration and facilitates uptake of allergens by antigen-presenting 
cells residing in the skin (e.g., Langerhans cells, dendritic cells), which subsequently induces cutaneous aller-
gen sensitization27,28. Therefore, genetic susceptibility towards defective epidermal barrier and deviated immune 
responses could work together in the development of allergic sensitization. The finding of possible epistasis 
between two functionally different genes that work in concert in the development of allergic disorders and sensi-
tization highlight the importance of considering epistasis (gene-gene interaction) in genetic association studies. 
Although the current report focuses on gene-gene interactions, considering gene-environment interactions is as 
important and should concurrently be incorporated in future studies to determine whether risks associated with 
environmental exposures are the same for people with different genetic susceptibilities.
Characteristic
IOW cohort
% (n/total)
MAAS cohort % 
(n/total)
Sex
Male 51.2 (745/1456) 54.5 (577/1058)
Female 48.8 (711/1456) 45.5 (481/1058)
Allergic sensitization at age
4 years 19.6 (192/982) —
5 years — 29.0 (240/827)
8 years — 32.8 (268/818)
10 years 26.9 (279/1036) —
11 years — 35.2 (256/728)
18 years 41.4 (353/853) —
IL4R rs3024676
AA 2.3 (26/1149) 3.3 (30/907)
AC 29.1 (335/1149) 29.2 (265/907)
CC 68.6 (788/1149) 67.5 (612/907)
MAF (allele A) 0.17 0.18
HWE P value 0.199 0.841
FLG variants
R501X 4.1 (47/1161) 4.6 (40/870)
2282del4 4.6 (54/1168) 4.5 (37/828)
S3247X 1.6 (18/1165) 0.8 (7/909)
FLG haploinsufficiency* 10.3 (118/1150) 9.9 (80/809)
Table 1. Characteristics of the IOW and MAAS (Caucasians only) cohort studies participants. MAF: Minor 
allele frequency; HWE: Hardy-Weinberg equilibrium. *Analyses were conducted using the combined carriage 
of a FLG null allele; that is, if a child carried 1 or more of the FLG variants R501X, 2282del4, or S3247X, he or 
she was classified as having filaggrin haploinsufficiency.
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Prior investigations have shown that epistasis between immune-specific genes contributes to the development 
of allergic sensitization (influence serum IgE levels). For instance, combining variants in IL4 (rs2243250), IL13 
(rs1800925), IL4R (rs1805010), and STAT6 (rs324011) genes was associated with a 10.8-fold increased risk of hav-
ing high serum IgE levels (i.e., IgE >457 IU/mL [>90th percentile])16. Moreover, a gene-gene interaction between 
IL13 and CCL17 (chemokine (C-C motif) ligand 17, also known as TARC: thymus and activation-regulated 
chemokine) variants increased the risk of having at least one positive allergen-specific IgE test response by 
3.9-fold29.
IL4R SNPs
Genetic 
Model† Genotype†
Interaction term 
(IL4R × FLG)‡
P value
rs8832 Additive GG/AG/AA 0.791
rs1110470 Additive GG/AG/AA 0.388
rs1805011 Heterosis AA/CC vs. AC 0.389
rs1805012 Dominant GG/AG vs. AA 0.929
rs2057768 Additive GG/AG/AA 0.412
rs3024604 Heterosis AA/GG vs. AG 0.891
rs3024676 Heterosis AA/CC vs. AC 0.003*
rs3024685 Additive GG/AG/AA 0.703
rs4787423 Recessive GG vs. AA/AG 0.649
rs6498012 Additive GG/CG/CC 0.878
rs12102586 Recessive AA vs. AG/GG 0.845
rs16976728 Dominant AA/AG vs. GG 0.809
Table 2. Evaluating statistical interaction effects (epistasis) between IL4R SNPs and FLG variants on the risk 
of allergic sensitization: results from IOW cohort study via longitudinal analyses. SNP: Single nucleotide 
polymorphism. *FDR corrected P value = 0.036. †For each IL4R SNP the best fitting genetic risk model 
(dominant, recessive, heterosis, or additive) was selected as detailed in the ‘Methods’ section. Under the 
additive model, the three genotypes were coded and entered in the regression model in a dosage-effect manner 
(from smaller to larger effect). For instance, the best fitting genetic risk model for SNP rs8832 is ‘additive’ 
model, meaning that the risk of allergic sensitization increases gradually from least risk among those with GG 
genotype to moderate risk among those with AG genotype to highest risk among those with AA genotype. 
In the ‘heterosis’ model we collapsed the two homozygote genotypes together and compare their risk to the 
heterozygote risk. For example, the best fitting genetic risk model for SNP rs1805011 is ‘heterosis’ model, in 
which the risk of homozygote genotypes (AA/CC) was compared to the risk of heterozygote genotype (AC). 
For SNP rs1805012, in the dominant model we compared the risk of variant homozygote and heterozygote 
(GG/AG) genotypes to the risk of wild-type homozygote (AA) genotype. For SNP rs4787423, in the recessive 
model we compared the risk of variant homozygote (GG) genotype to the risk of wild-type homozygote 
and heterozygote (AA/AG) genotypes. ‡Interaction term refers to the product term that we included in the 
regression model to test for the presence of multiplicative statistical interaction between FLG variants and IL4R 
SNPs. Since there are 12 IL4R SNPs, we tested 12 interaction terms (IL4R SNP × FLG variants), while using the 
best fitting genetic risk model for each IL4R SNP.
Allergic sensitization at age
FLG variants IL4R rs3024676 genotype
WT LOF AC AA/CC
4 years, % (n/total) 19.6 (147/751) 27.2 (25/92) 19.2 (46/240) 21.3 (129/605)
OR (95% CI)* 1.00 1.51 (0.92–2.47) 1.00 1.15 (0.79–1.68)
P value 0.105 0.468
10 years, % (n/total) 26.4 (227/859) 41.1 (39/95) 22.2 (63/284) 30.2 (201/666)
OR (95% CI)* 1.00 1.89 (1.22–2.93) 1.00 1.56 (1.12–2.16)
P value 0.004 0.008
18 years, % (n/total) 41.3 (293/709) 50.6 (43/85) 38.1 (86/226) 44.0 (250/568)
OR (95% CI)* 1.00 1.41 (0.89–2.23) 1.00 1.32 (0.96–1.81)
P value 0.140 0.090
Repeated measurements, % (k/total)† 28.8 (667/2319) 39.3 (107/272) 26.0 (195/750) 31.5 (580/1839)
OR (95% CI) 1.00 1.47 (1.01–2.14) 1.00 1.25 (0.97–1.62)
P value 0.046 0.085
Table 3. Association of FLG variants and IL4R rs3024676 with allergic sensitization: results from IOW cohort 
study. FLG WT: FLG wild-type genotype; FLG LOF: FLG loss-of-function genotype; k = number of repeated 
measurements. *Association adjusted for sex. †Association adjusted for sex and age at follow-up.
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The current study further confirmed the previously noted association between FLG variants and allergic sen-
sitization10 and added that this association is modified by IL4R rs3024676 SNP. The observed epistasis suggests 
that FLG variants exert their adverse effect only among individuals carrying the homozygous genotypes of IL4R 
rs3024676 SNP. Surprisingly, FLG variants posed no increased risk of allergic sensitization if individuals carried 
the heterozygous genotype of IL4R rs3024676 SNP. Hence, indicating that carrying the two alleles (A and C) of 
IL4R rs3024676 SNP masked the effect of FLG variants. In this sense, having a heterozygous genotype of IL4R 
rs3024676 SNP is advantageous for individuals carrying FLG variants. The ‘heterozygote advantage’ (heterosis) 
phenomenon, whereby carrying two different versions of the gene (heterozygous genotype) is more advantageous 
than having two copies of the same allele (homozygous genotype), has long been recognized in animal and plant 
genetics, but largely overlooked in human genetic studies30,31. Although rarely investigated, heterosis is believed 
to be a common phenomenon in humans and not accounting for the heterotic effect hinders the success of genetic 
linkage and association studies32,33. A classic example of ‘heterozygote advantage’ is demonstrated through the 
elevated tolerance/resistance to malaria infection among individuals who are heterozygous for sickle cell anemia 
causing-allele as compared to those who are homozygous at this locus34.
To corroborate the observed differential effect of the heterozygous genotype (heterosis model) of IL4R 
rs3024676, we assessed associations between genotypes of IL4R rs3024676 SNP with IL-4 cytokine levels meas-
ured in serum of subset of IOW study participants aged 10 years. Results of this proof-of-concept analysis 
showed that serum levels of IL-4 cytokine varies cross genotypes of IL4R rs3024676 with higher levels observed 
among participants carrying the heterozygous genotype compared to those carrying the homozygous geno-
types (P = 0.10; see Supplementary Table S3). Moreover, since DNA methylation was measured in blood sam-
ples of a subset of IOW study participants, we further investigated whether DNA methylation levels at CpG 
(cytosine-phosphate-guanine) sites within the IL4R gene are associated with genotypes of IL4R rs3024676 SNP. 
Allergic sensitization at age
IL4R rs3024676 Homozygous (AA/
CC) IL4R rs3024676 Heterozygous (AC)
FLG WT FLG LOF FLG WT FLG LOF
4 years, % (n/total) 20.1 (107/532) 30.3 (20/66) 18.3 (39/213) 21.7 (5/23)
OR (95% CI)* 1.00 1.71 (0.97–3.01) 1.00 1.20 (0.42–3.44)
P value 0.064 0.738
10 years, % (n/total) 28.2 (168/595) 50.0 (31/62) 22.8 (57/250) 20.7 (6/29)
OR (95% CI)* 1.00 2.55 (1.50–4.35) 1.00 0.86 (0.33–2.23)
P value  < 0.001 0.762
18 years, % (n/total) 42.3 (212/501) 60.7 (37/61) 40.5 (81/200) 19.1 (4/21)
OR (95% CI)* 1.00 2.07 (1.20–3.59) 1.00 0.32 (0.10–0.99)
P value 0.009 0.048
Repeated measurements, % (k/total)† 29.9 (487/1628) 46.6 (88/189) 26.7 (177/663) 20.6 (15/73)
OR (95% CI) 1.00 1.97 (1.27–3.05) 1.00 0.53 (0.22–1.32)
P value 0.003 0.175
Table 4. Association of FLG variants with allergic sensitization stratified by IL4R rs3024676 genotypes: 
results from IOW cohort study. FLG WT: FLG wild-type genotype; FLG LOF: FLG loss-of-function genotype; 
k = number of repeated measurements. *Association adjusted for sex. †Association adjusted for sex and age at 
follow-up.
Allergic sensitization at age
FLG variants IL4R rs3024676 genotype
WT LOF AC AA/CC
5 years, % (n/total) 28.2 (187/662) 44.8 (30/67) 29.8 (67/225) 28.9 (157/543)
OR (95% CI)* 1.00 1.97 (1.18–3.30) 1.00 0.97 (0.69–1.37)
P value 0.010 0.871
8 years, % (n/total) 31.3 (202/646) 48.6 (36/74) 35.0 (76/217) 31.1 (169/543)
OR (95% CI)* 1.00 2.05 (1.25–3.35) 1.00 0.84 (0.60–1.18)
P value 0.004 0.321
11 years, % (n/total) 34.8 (202/581) 43.8 (28/64) 39.6 (76/192) 32.5 (159/489)
OR (95% CI)* 1.00 1.47 (0.86–2.49) 1.00 0.74 (0.52–1.04)
P value 0.155 0.087
Repeated measurements, % (k/total)† 31.3 (591/1889) 45.9 (94/205) 34.5 (219/634) 30.8 (485/1575)
OR (95% CI) 1.00 1.73 (1.13–2.63) 1.00 0.87 (0.65–1.15)
P value 0.011 0.328
Table 5. Association of FLG variants and IL4R rs3024676 with allergic sensitization: results from MAAS cohort 
study FLG WT: FLG wild-type genotype; FLG LOF: FLG loss-of-function genotype; k = number of repeated 
measurements. *Association adjusted for sex. †Association adjusted for sex and age at follow-up.
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Results of this analysis showed that levels of DNA methylation of IL4R CpG site to be lower among participants 
with the heterozygous genotype of IL4R rs3024676 SNP compared to participants with homozygous genotypes 
(P = 0.001; see Supplementary Table S4). Hence, the previous findings strengthen the plausibility of a heterosis 
model. However, further investigations from a genetic point of view, e.g., through experiments, are needed to 
conform the mechanistic plausibility of the heterosis model.
The longitudinal design of both the IOW and MAAS cohort studies that prospectively ascertained allergic 
sensitization status through repeated skin prick testing is a major strength of the current study. Applying repeated 
measurements analysis helped in minimizing the effect of misclassification, if any is present, on the results of 
this report. Moreover, in both studies the proportions of children who participated in SPTs remained reasonably 
high throughout the follow-ups. In the IOW cohort study, SPT was performed on 982 (80%), 1036 (75%), and 
853 (65%) of those who participated in the 4-, 10-, and 18-years follow-ups, respectively. In a previous report 
we demonstrated that there is no indication of selection bias in terms of participants undergoing skin prick 
testing at each assessment in regard to various phenotypes35. In the MAAS cohort study, information on allergic 
sensitization status was available for 827 (78%), 818 (77%), and 728 (69%) participants at ages 5, 8, and 11 years, 
respectively. The slight discrepancies in the prevalence of allergic sensitization between the IOW and MAAS 
cohort studies can be explained by the different timing (age of participants) of ascertainment. In the stratified 
analyses by IL4R rs3024676 genotypes, the association of FLG variants with allergic sensitization among IL4R 
rs3024676 homozygotes showed agreement in regard to the direction of the effect measure and statistical signifi-
cance in both studies (IOW: OR, 1.97, P = 0.003, Table 4; MAAS: OR, 1.93, P = 0.017, Table 6). In contrast, among 
IL4R rs3024676 heterozygotes the direction of the effect measure disagreed across the two studies (IOW: OR, 
0.53, P = 0.175, Table 4; MAAS: OR, 1.44, P = 0.360, Table 6); however, this inconsistency has no impact on our 
findings/conclusions due to the lack of statistical significance in either study and the consistent/strong combined 
effect of IL4R AA/CC and FLG variants on the risk of allergic sensitization in both studies (see Supplementary 
Fig. S2). On a multiplicative scale, the statistical significance of the interaction term (IL4R rs3024676 × FLG 
variants) that was observed in the IOW study was not replicated in the MAAS cohort. However, observing an 
association between FLG variants and allergic sensitization among IL4R rs3024676 homozygotes in both studies 
and the absence of such association among IL4R rs3024676 heterozygotes indicates that IL4R rs3024676 SNP is 
a potential effect modifier and that the findings were consistent with regard to their directionality a statistical 
significance in both studies among IL4R rs3024676 homozygotes. Although the signal for a statistical epistasis 
was moderate and marginally replicated, the functional evidence, i.e. differential serum levels of IL-4 cytokine 
and DNA methylation levels at CpG sites within the IL4R gene among participants with heterozygous genotype 
of IL4R rs3024676 SNP compared to participants with homozygous genotypes (see Supplementary Table S3 and 
Table S4), further strengthens the evidence of possible epistatic effect and the plausibility of a heterosis risk model. 
Future studies are needed to corroborate our findings.
IL4R rs3024676 SNP is an intron polymorphism, thus its epistatic effect may be due to its being in linkage dis-
equilibrium with a functional variant that is responsible for the observed epistatic effect. However, a prior inves-
tigation has shown that IL4R rs3024676 SNP is part of an interaction of six genes affecting pediatric asthma36. 
Another drawback is the use of OR as effect measure, which can overestimate the risk ratio when the outcome is 
common (i.e., >10%)37. To assess the possible overestimation, using IOW cohort study data, we estimated the risk 
ratio for the association between FLG variants and allergic sensitization among those who carry the homozygous 
genotypes of IL4R rs3024676 SNP; the risk ratio estimate is 1.40 (95% CI, 1.13–1.75; P = 0.003) and the reported 
OR is 1.97 (95% CI, 1.27–3.05; P = 0.003). In both approaches the statistical significance did not change, but the 
magnitude of the effect was influenced by the choice of the effect measure. In the current study we estimated ORs 
using logistic regression due to its availability to both research groups.
Allergic sensitization at age
IL4R rs3024676 Homozygous (AA/
CC) IL4R rs3024676 Heterozygous (AC)
FLG WT FLG LOF FLG WT FLG LOF
5 years, % (n/total) 28.2 (124/439) 46.2 (18/39) 28.6 (52/182) 42.9 (9/21)
OR (95% CI)* 1.00 2.11 (1.08–4.11) 1.00 1.74 (0.68–4.45)
P value 0.028 0.249
8 years, % (n/total) 29.4 (128/436) 52.2 (24/46) 33.9 (58/171) 45.5 (10/22)
OR (95% CI)* 1.00 2.58 (1.39–4.81) 1.00 1.60 (0.65–3.94)
P value 0.003 0.307
11 years, % (n/total) 31.8 (125/393) 45.0 (18/40) 40.0 (62/155) 41.2 (7/17)
OR (95% CI)* 1.00 1.71 (0.88–3.34) 1.00 1.08 (0.39–2.99)
P value 0.115 0.889
Repeated measurements, % (k/total)† 29.7 (377/1268) 48.0 (60/125) 33.9 (172/508) 43.3 (26/60)
OR (95% CI) 1.00 1.93 (1.12–3.31) 1.00 1.44 (0.66–3.12)
P value 0.017 0.360
Table 6. Association of FLG variants with allergic sensitization stratified by IL4R rs3024676 genotypes: results 
from MAAS cohort study. FLG WT: FLG wild-type genotype; FLG LOF: FLG loss-of-function genotype; 
k = number of repeated measurements. *Association adjusted for sex. †Association adjusted for sex and age at 
follow-up.
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In conclusion, the current study demonstrates, for the first time, that epistatic effect (gene-gene interaction) 
between immune (IL4R) and skin (FLG) regulatory genes exist in the pathogenesis of allergic sensitization in two 
independent epidemiological studies. FLG variants predisposed to increased risk of allergic sensitization among 
those who carry the homozygous genotypes of IL4R rs3024676 SNP; whereas, FLG variants effect was masked 
among those who are heterozygous for IL4R rs3024676 SNP. Based on results of this report, it is plausible that 
epidermal barrier and immune regulatory genes act synergistically (or additively) in the development of allergic 
sensitization. Hence, the observed epistasis provides insight on possible mechanisms underlying the development 
of allergic sensitization.
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